JPM 2023 Presentation vFF (1.8.23 6.20 PM) 安进.pdf

《JPM 2023 Presentation vFF (1.8.23 6.20 PM) 安进.pdf》由会员分享，可在线阅读，更多相关《JPM 2023 Presentation vFF (1.8.23 6.20 PM) 安进.pdf（20页珍藏版）》请在三个皮匠报告上搜索。

1、ROBERT A.BRADWAYCHAIRMAN AND CHIEF EXECUTIVE OFFICER41ST ANNUAL J.P.MORGAN HEALTHCARE CONFERENCEJanuary 9,20232Provided January 9,2023,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen disclaims any duty to update.Th

2、is presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen.All statements,other than statements of historical fact,are statements thatcould be deemed forward-looking statements,including any statements on the outcome,benefits and synergies of

3、collaborations,or potential collaborations,with any other company(includingBeiGene,Ltd.,Kyowa-Kirin Co.,Ltd.,or any collaboration to manufacture therapeutic antibodies against COVID-19),the performance of Otezla(apremilast)(including anticipated Otezla salesgrowth and the timing of non-GAAP EPS accr

4、etion),the Five Prime Therapeutics,Inc.acquisition,the Teneobio,Inc.acquisition,the ChemoCentryx,Inc.acquisition,or the proposed acquisition ofHorizon Therapeutics plc,as well as estimates of revenues,operating margins,capital expenditures,cash,other financial metrics,expected legal,arbitration,poli

5、tical,regulatory or clinical results orpractices,customer and prescriber patterns or practices,reimbursement activities and outcomes,effects of pandemics or other widespread health problems such as the ongoing COVID-19pandemic on our business,outcomes,progress,and other such estimates and results.Fo

6、rward-looking statements involve significant risks and uncertainties,including those discussed below and morefully described in the Securities and Exchange Commission reports filed by Amgen,including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q andcurre